LUPIN TO CONDUCT TRIALS OF PSORIASIS DRUG

Lupin has received approval from the Drug Controller General of India for conducting Phase II clinical trials of its investigation new drug candidate LLL-3348 (Desoris), which is a proposed treatment of moderate-to-severe chronic stable plaque-type psoriasis.

The approval comes after the company's successful completion of the therapeutic evaluation and safety profiling of Desoris in Phase I single- and multiple-dose study in healthy volunteers. Desoris will now be evaluated for efficacy in patients in a Phase II clinical trial at 10 sites across India.